Novel opportunities for therapeutic targeting in systemic autoimmune diseases

Methods in Molecular Biology

Volumn 361, Issue , 2007, Pages 285-297

  Ouarzane, Meryem ^a   Zouali, Moncef ^a  

^a NONE

Author keywords

Autoimmune diseases; B lymphocytes; Complement components; Rheumatoid arthritis; Signaling; Systemic lupus erythematosus; TNFa

Indexed keywords

B CELL ACTIVATING FACTOR; FC GAMMA RECEPTOR IIB; FC RECEPTOR; LEUKOCYTE ANTIGEN; TNFSF13B PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL; AUTOIMMUNE DISEASE; B LYMPHOCYTE; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; IMMUNOLOGY; LEUKAPHERESIS; METHODOLOGY; PATHOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD; AUTOIMMUNE DISEASES; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; HUMANS; LEUKOCYTE REDUCTION PROCEDURES; RECEPTORS, IGG; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION;

EID: 34247637048     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1385/1-59745-208-4:285     Document Type: Article

References (51)

1. Kappler, J. W., Roehm, N., and Marrack, P. (1987) T cell tolerance by clonal elimination in the thymus. Cell 49, 273-280.
2. Kappler, J. W., Staerz, U., White, J., and Marrack, P. C. (1988) Self-tolerance eliminates T cells specific for Mis-modified products of the major histocompatibility complex. Nature 332, 35-40.
3. Nemazee, D. and Buerki, K. (1989) Clonal deletion of autoreactive B lymphocytes in bone marrow chimeras. Proc. Natl. Acad. Sci. USA 86, 8039-8043.
4. Nossal, G. J. and Pike, B. L. (1980) Clonal anergy: persistence in tolerant mice of antigen-binding B lymphocytes incapable of responding to antigen or mitogen. Proc. Natl. Acad. Sci. USA 11, 1602-1606.
5. Tiegs, S. L., Russell, D. M., and Nemazee, D. (1993) Receptor editing in selfreactive bone marrow B cells. J. Exp. Med. 177, 1009-1020.
6. Radie, M. Z., Erikson, J., Litwin, S., and Weigert, M. (1993) B lymphocytes may escape tolerance by revising their antigen receptors. J. Exp. Med. Ill, 1165-1173.
7. Radic, M. Z. and Zouali, M. (1996) Receptor editing, immune diversification, and self-tolerance. Immunity 5, 505-511.
8. Bouneaud, C., Kourilsky, P., and Bousso, P. (2000) Impact of negative selection on the T cell repertoire reactive to a self-peptide: a large fraction of T cell clones escapes clonal deletion. Immunity 13, 829-840.
9. Yan, J. and Mamula, M. J. (2002) Autoreactive T cells revealed in the normal repertoire: escape from negative selection and peripheral tolerance. J. Immunol. 168, 3188-3194.
10. Zouali, M. (2005) Taming lupus. Sci. Am. 292, 70-77.
11. Choy, E. H. and Panayi, G. S. (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl. J. Med. 344, 907-916.
12. Viau, M. and Zouali, M. (2005) B-lymphocytes, innate immunity, and autoimmunity. Clin. Immunol. 114, 17-26.
13. Uchida, J., Hamaguchi, Y., Oliver, J. A., et al. (2004) The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. 199, 1659-1669.
14. Goldblatt, F. and Isenberg, D. A. (2005). New therapies for rheumatoid arthritis. Clin. Exp. Immunol. 140, 195-204.
15. Leandro, M. J., Edwards, J. C., and Cambridge, G. (2002) Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann. Rheum. Dis. 61, 883-888.
16. Edwards, J. C., Szczepanski, L., Szechinski, J., et al. (2004) Efficacy of B-celltargeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350, 2572-2581.
17. Leandro, M. J., Edwards, J. C., Cambridge, G., Ehrenstein, M. R., and Isenberg, D. A. (2002) An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 46, 2673-2677.
18. Tokunaga, M., Fujii, K., Saito, K., et al. (2005) Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology (Oxford) 44, 176-182.
19. Zouali, M. (2002) B cell diversity and longevity in systemic autoimmunity. Mol. Immunol. 38, 895-901.
20. Ng, L. G., Mackay, C. R., and Mackay, F. (2005) The BAFF/APRIL system: life beyond B lymphocytes. Mol. Immunol. 42,763-772.
21. Gross, J. A., Johnston, J., Mudri, S., et al. (2000) TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404, 995-999.
22. Yan, M., Brady, J. R., Chan, B., et al. (2001) Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Curr. Biol. 11, 1547-1552.
23. Cheema, G. S., Roschke, V., Hubert, D. M., and Stohl, W. (2001) Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 44, 1313-1319.
24. Stohl, W., Metyas, S., Tan, S. M., et al. (2003) B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum. 48, 3475-3486.
25. Bolland, S. and Ravetch, J. V. (2000) Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis. Immunity 13, 277-285.
26. McGaha, T. L., Sorrentino, B., and Ravetch, J. V. (2005) Restoration of tolerance in lupus by targeted inhibitory receptor expression. Science 307, 590-593.
27. Zouali, M. and Sarmay, G. (2004) B lymphocyte signaling pathways in systemic autoimmunity: implications for pathogenesis and treatment. Arthritis Rheum. 50, 2730-2741.
28. Watanabe, H., Gamier, G., Circolo, A., et al. (2000) Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B. J. Immunol. 164, 786-794.
29. Holers, V. M. (2003) The complement system as a therapeutic target in autoimmunity. Clin. Immunol. 107, 140-151.
30. Neumann, E., Barnum, S. R., Tarner, I. H., et al. (2002) Local production of complement proteins in rheumatoid arthritis synovium. Arthritis Rheum. 46, 934-945.
31. Steinman, R. M. and Nussenzweig, M. C. (2002) Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc. Natl. Acad. Sci. USA 99, 351-358.
32. Blanco, P., Palucka, A. K., Gill, M., Pascual, V., and Banchereau, J. (2001) Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 294, 1540-1543.
33. Pascual, V., Banchereau, J., and Palucka, A. K. (2003) The central role of dendritic cells and interferon-alpha in SLE. Curr. Opin. Rheumatol. 15, 548-556.
34. Kalkner, K. M., Ronnblom, L., Karlsson Parra, A. K., Bengtsson, M., Olsson, Y., and Oberg, K. (1998) Antibodies against double-stranded DNA and development of polymyositis during treatment with interferon. Qjm 91, 393-399.
35. Ronnblom, L. E., Aim, G. V., and Oberg, K. (1991) Autoimmune phenomena in patients with malignant carcinoid tumors during interferon-alpha treatment. Acta Oncol. 30, 537-540.
36. Ronnblom, L. and Aim, G. V. (2001) A pivotal role for the natural interferon alphaproducing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus. J. Exp. Med. 194, F59-F63.
37. Baechler, E. C., Gregersen, P. K., and Behrens, T. W (2004) The emerging role of interferon in human systemic lupus erythematosus. Curr. Opin. Immunol. 16, 801-807.
38. Taylor, P. C., Peters, A. M., Paleolog, E., et al. (2000) Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum. 43, 38-47.
39. Voulgari, P. V., Alamanos, Y., Nikas, S. N., Bougias, D. V., Temekonidis, T. I., and Drosos, A. A. (2005) Infliximab therapy in established rheumatoid arthritis: an observational study. Am. J. Med. 118, 515-520.
40. Emery, P. (2005) Adalimumab therapy: clinical findings and implications for integration into clinical guidelines for rheumatoid arthritis. Drugs Today (Bare) 41, 155-163.
41. Sokol, M. C. (2005) Effective coverage and reim bursement strate etanercept and infliximab in the treatment of rheumatoid arthritis. Manag. Care Interface 18, 32-37.
42. Bezerra, M. C., Carvalho, J. F., Prokopowitsch, A. S., and Pereira, R. M. (2005) RANK, RANKL and osteoprotegerin in arthritic bone loss. Braz. J. Med. Biol. Res. 38, 161-170.
43. Boyle, W. J., Simonet, W. S., and Lacey, D. L. (2003) Osteoclast differentiation and activation. Nature 423, 337-342.
44. Yun, T. J., Tallquist, M. D., Aicher, A., et al. (2001) Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function. J. Immunol. 166, 1482-1491.
45. Kong, Y. Y., Yoshida, H., Sarosi, I., et al. (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397, 315-323.
46. Cheng, G. and Schoenberger, S. P. (2002) CD40 signaling and autoimmunity. Curr. Dir. Autoimmun. 5, 51-61.
47. Datta, S. K. and Railed, S. L. (1997) CD40-CD40 ligand interaction in autoimmune disease. Arthritis Rheum. 40, 1735-1745.
48. Crow, M. K. and Kirou, K. A. (2001) Regulation of CD40 ligand expression in systemic lupus erythematosus. Curr. Opin. Rheumatol. 13, 361-369.
49. Toubi, E. and Shoenfeld, Y. (2004) The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway. Autoimmunity 37, 457-464.
50. Grammer, A. C., Slota, R., Fischer, R., et al. (2003) Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD 154CD40 interactions. J. Clin. Invest. 112, 1506-1520.
51. Morel, J. and Berenbaum, E (2004) Signal transduction pathways: new targets for treating rheumatoid arthritis. Joint Bone Spine 71, 503-510.